Pharmacokinetics and Toxicities after Evomela ® (Propylene Glycol Free Melphalan) with Hematopoietic Stem Cell Transplant (HCT) for Multiple Myeloma (MM), AL Amyloidosis (AL), Lymphoma, Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS)

Background: Melphalan exposure as measured by area under the curve (AUC) has a 5-fold variability between pts, with higher AUCs associated with improved outcomes but increased toxicity (Shaw BBMT 2012). Evomela ® (propylene glycol free melphalan, PGF-MEL) is an intravenous formulation with improved stability and possibly less toxicity related to the solubilizing agent. We aimed to determine the pharmacokinetics (PK) and relationship between exposure and toxicities with this formulation in order to optimiz e dosing.

Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Gunjan L. Shah, Heather Landau, Caitlin Sarubbi, Ryan Schofield, Andrew Lin, Valkal Bhatt, Stephen Harnicar, Sean M. Devlin, Hugo Castro-Malaspina, David J. Chung, Parastoo B. Dahi, Boglarka Gyurkocza, Guenther Koehne, Matthew J. Matasar, Craig H. Moskowi Source Type: research